Rob Davis, Merck CEO (Jeenah Moon/Bloomberg via Getty Images)
Another quarter, another Keytruda win for Merck
Merck posted yet another strong quarter on the back of its cancer therapy Keytruda, in what’s becoming almost a routine event for the New Jersey …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
